Season1103 (@Season11031) profile picture
Joined June 2022
If you look at RO of 480 and 720mg, RO averages similar between them but 720 much lower variance in RO. In retro, would you have chosen 720 as RP2D? If 720 $AFMD would be celebrating now since ORR>30%/PFS>6month is a lock for approval for heavily pretreated CPI-refractory NSCLC
1
2
4
739
Replying to @avidresearch
What $SMMT seeing in clinic is the same HR seen with avastin in 2006 when compared to chemotherapy alone then. This is why $MRK who knows the field well is not buying into the story. And this enrichement of PD1 in tumor micro environment is irrelevant as kytruda saturates PD1 at even half approved dose and there was no extra advantage when given 5 folds approved dose. N Engl J Med 2015;372:2521-2532 DOI: 10.1056/NEJMoa1503093
3
3
9
1,173
Season1103 retweeted
$afmd Canino on call suggesting that atezo is driving efficacy in 24 data. On PD-1 refractory px's. Classic ๐Ÿคก
2
1
7
1,132
My first words for new CEO Shawn Leland of $AFMD: look into $IBRX ImmunityBioโ€™s Anktiva that activates NK cells in vivo and works in NSCLC. I expect big synergy between Anktiva and AFM24. Sign a deal with $IBRX, do a first line combo trial for NSCLC, then expand to other cancers.
2
5
1,094
Potentially other AFMxx + Anktiva combo can work without NK cell infusions, making Anktiva and AFMxx blockbusters. Shawn, make 3 blockbusters for $AFMD!
1
3
536
Other combos and NK cell therapies are dropping like flies, makes it more and more valuable the last man (or girl, if you are for political correctness, but money has no gender) standing: $AFMD
1
5
271
$AFMD short interest published today at 4 pm. We will know what more about happened during the strange days June 3 and 12 when 31M shares, twice the float, traded.
1
1
585
Almost all my $AFMD shares at my brokerage have been lended to shorting recent days. Love to see a short squeeze bankrupts several hedge funds, and makes many Jesse Livermores.
4
3
758
$AFMD short interest only increased about 2 fold to 922k, 6% of float. Itโ€™s perplexing who were trading 31M shares on June 3.
219
Season1103 retweeted
Replying to @BowTiedBiotech
$AFMD 13 turns macrophages, CBNK and endogenous NK into defacto CARNK and CARM. #crispr NK ACTs are 1 trick ponies and don't activate macrophages directly. Cytokines from these modified NKs last as long as the MDACC secret sauce.
2
1
4
494
Season1103 retweeted
IPHA and Dragonfly Abs are monomeric CD16a, not enough activation on macrophage compared ICEs. They work in PB, not so well in BM and wherever TAM dominate.
2
1
4
1,116
Season1103 retweeted
$afmd AFM12?--Do we have a CD19 targeting ICE ? The reacquisition of afm32 got me wondering what else the co. might have in the cupboard that could prove attractive to a potential partner/acquirer as the modality gains steam . . . I was reminded of that SITC poster last year showing that a simple ICE + nk cell approach was at least as powerful as an engineered CAR-nk approach. To compare both approaches, they evaluated nk cells combined with a "CD19/CD16A-targeting ICEยฎ" versus anti-CD19 CAR-NK cells. " Huh?๐Ÿค”That sounds proprietary doesn't it . . . and, at a time, when everybody and their grandmother has pivoted to auto-immune . . . A little extra digging turned up this reference to AFM 12. Very interesting if this asset is sitting on the shelf back in Mannheim. Does anybody out there in the affimedisphere know what's happened to AMF 12?
2
3
2
11
4,214
Season1103 retweeted
@Biotech777 Hiring a competitor to design and run $AFMD clinical trial should be the top reason to fire the CEO and CSO. MDACC has nothing to do with LuminICE now. The board figured out they were taken for a ride.
1
1
6
557
Season1103 retweeted
Why bother with CART and CARNK and worry about off target editing when $AFMD ICE can turn off the shelf CBNK into effective targeted ACT? Why no journalist or Wall St. analyst understand the implication? $2000 price tag on a bag of CBNK makes many bios existence questionable.
2
3
10
1,314
Season1103 retweeted
Did you listen ER call yet. You can find answers for all your questions from the call $AFMD
1
1
1
408
Replying to @ny1972_47 @qclark12
Indeed, for CD19 we know it from $AFMD prior preclinical work with Standford (and $RHBBY will know as well ;) ) nitter.cf/dhovekamp42/status/111โ€ฆ
$AFMD #AFM11 CD19 T-cell engager + #AFM12 CD19 NK-cell engager + Anti-PD1/PDL1 a first example of Affimed combination (&deal) potential with $RHHBY Genentech / $MRK Merck / $BMS and other immunesystem adjuvants
1
3
628